Search results
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company...
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
Zacks via Yahoo Finance· 6 months agoAxsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat...
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Zacks via Yahoo Finance· 2 months agoAxsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol...
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?
Zacks via Yahoo Finance· 2 years agoAxsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects....
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
Zacks via Yahoo Finance· 2 years agoThe FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major...
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
Zacks via Yahoo Finance· 1 year agoAxsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The...
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. AXSM incurred an adjusted loss 22 cents per share in the first quarter of...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics AXSM announced that the first patient has been enrolled in the ADVANCE-2 phase...
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
Investor's Business Daily· 1 year agoTeva Pharmaceutical said Monday it plans a competing knockoff of Axsome Therapeutics' new depression...